Cloud-based opportunities Rapid has recent momentum in cloud-based radiopharmaceutical data solutions with a $2M NIH grant to develop cloud-based quantitative SPECT reconstruction. This signals potential alignment with partners or customers seeking scalable, cloud-enabled dosimetry and data analytics services.

Multi-center readiness The company specializes in protocols and FDA-ready reports for multi-center trials, indicating a strong fit for institutions seeking standardized, compliant dosimetry and trial reporting. Sales opportunities could target large research hospitals and imaging centers running multicenter radiopharmaceutical studies.

Clinical workflow support Full-service consulting from protocol development to regulatory reporting suggests value in end-to-end workflow optimization. Potential upsell to sites needing CRO-like support, data harmonization, and streamlined FDA submissions.

Funding credibility Significant NIH grant activity demonstrates credibility and investment in radiopharmaceutical technologies, which can be leveraged in outreach to grant-funded programs and academic centers pursuing similar funding trajectories.

Pricing and scale fit Revenue in the low-to-mid single digits of millions with a lean team (11-50 employees) implies agility but niche scale. Target mid-sized imaging centers and regional hospitals seeking expert dosimetry consulting with cost-efficient, outsized impact.